Important security notice Important security notice: CIGP is not associated with thunderplan[.]hk

CIGP is not associated with thunderplan[.]hk, the “Thunder Break” investment scheme or any related WhatsApp group or message and has not authorised or endorsed any of them. Do not send money or personal information in connection with any of them; verify any approach made in CIGP’s name directly with us using the contact details published on this website.

Notis keselamatan penting Notis keselamatan penting: CIGP tidak mempunyai sebarang kaitan dengan thunderplan[.]hk

CIGP tidak mempunyai sebarang kaitan dengan thunderplan[.]hk, skim pelaburan “Thunder Break” atau mana-mana kumpulan atau mesej WhatsApp yang berkaitan dan tidak pernah membenarkan atau menyokong mana-mana satu daripadanya. Jangan hantar wang atau maklumat peribadi berkaitan dengan mana-mana satu daripadanya; sahkan sebarang pendekatan yang dibuat atas nama CIGP secara terus dengan kami menggunakan butiran hubungan yang diterbitkan di laman web ini.

Disclaimer

By accepting this, you are confirming that:

- You acknowledge and agree with our Cookie Policy (Learn more) and our Terms of Use (Learn more)
- You acknowledge and agree that Compagnie d'Investissements et de Gestion Privée (Hong Kong) Limited is licensed and regulated by the Hong Kong Securities and Futures Commission ("SFC") to conduct Type 1 (Dealing in securities), Type 4 (Advising on securities) and Type 9 (Asset management) activities (Learn more), and that it can only provide such regulated activities to Professional Investors according to the Securities and Futures Ordinance (Cap 571. Laws of Hong Kong) and its subsidiary legislation.

Disclaimer

By accepting this, you are confirming that:

- You acknowledge and agree with our Cookie Policy (Learn more) and our Terms of Use (Learn more)
- You acknowledge and agree that Compagnie d'Investissements et de Gestion Privée (Hong Kong) Limited is licensed and regulated by the Hong Kong Securities and Futures Commission ("SFC") to conduct Type 1 (Dealing in securities), Type 4 (Advising on securities) and Type 9 (Asset management) activities (Learn more), and that it can only provide such regulated activities to Professional Investors according to the Securities and Futures Ordinance (Cap 571. Laws of Hong Kong) and its subsidiary legislation.

I decline

Disclaimer

By accepting to visit this website, you are confirming that:

- You acknowledge and agree that all the information presented on this website refer to the activities of CIGP as a group of related companies and not to a specific CIGP entity, subsidiary or branch.

- You acknowledge and understand that in Switzerland, CIGP Compagnie d'Investissements et de Gestion Privée SA provides Portfolio Management services. All of the following services referred to on this website are not provided in Switzerland: Corporate Services (Global Custody, Financing, Transaction Services, Cash Management, Fund Structuring & Administration), Fund Advisory, Direct Investments, and Investment Banking (Global Financing and Sales & Trading).

- To understand the specific services provided in a specific location, please contact the relevant entity via our Contact us form.
- You acknowledge and agree with our Cookie Policy (Learn more) and our Terms of Use (Learn more).

I decline

Valuation of a Malaysian Biopharmaceutical Startup

CIGP performed an independent valuation analysis of a Malaysian clinical-stage biopharma company, contributing to its preparation for a planned listing on the New York Stock Exchange (“NYSE”).
 

Transaction Highlights

CIGP was mandated by Medika Natura, a Malaysian pre-revenue, clinical-stage biopharma company, to perform an independent valuation analysis of its pharmaceutical pipeline. The company specializes in the development of supplements and botanical drugs ahead of its listing on the New York Stock Exchange (NYSE).


CIGP’s valuation report was provided for supporting internal management decision-making and facilitating external investors’ due diligence in the context of the company’s pre-IPO capital raising efforts.
 

Role of CIGP

Comprehensive valuation: Leveraging its pharma expertise and emerging-market insights, CIGP conducted a thorough review of the drug pipeline and business plan for this pre-revenue biopharma firm, applying probability-adjusted modelling, milestone-driven analysis, and peer-comparable benchmarks to deliver a robust independent valuation.


Capital market expertise: CIGP conducted a critical evaluation of the company’s capital plans, incorporating the anticipated pre-IPO fundraising and IPO into the financial modelling to more accurately reflect the future capital structure and financing strategy.
 

Valuation of an Asian Healthtech Company